BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) has announced that CEO Chuck Kummeth will present at the Fifth Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 8:50 a.m. EST. The presentation will be available via a live webcast on Bio-Techne's Investor Relations website. The company is a prominent developer of purified proteins, reagents, and diagnostic products, generating approximately $1.1 billion in net sales in fiscal 2022. Bio-Techne serves biomedical researchers and clinical laboratories with a wide range of innovative solutions, employing around 3,000 staff globally.

MINNEAPOLIS, Nov. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Fifth Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 8:50 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide.

Contact:  David Clair, Vice President, Investor Relations
                david.clair@bio-techne.com
                612-656-4416  

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-fifth-annual-evercore-isi-healthconx-conference-301687360.html

SOURCE Bio-Techne Corporation

FAQ

What is the date and time of Bio-Techne's presentation at the HealthCONx Conference?

Bio-Techne's presentation at the HealthCONx Conference is scheduled for November 29, 2022, at 8:50 a.m. EST.

Where can I watch the live webcast of Bio-Techne's presentation?

The live webcast of Bio-Techne's presentation can be accessed on the Investor Relations website at https://investors.bio-techne.com/ir-calendar.

What are the key products offered by Bio-Techne Corporation?

Bio-Techne Corporation offers purified proteins, reagent solutions, diagnostics, and genomic tools, including cytokines, antibodies, and clinical diagnostic assays.

How much revenue did Bio-Techne generate in fiscal 2022?

Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022.

What segments does Bio-Techne operate in?

Bio-Techne operates in two main segments: Protein Sciences and Diagnostics and Genomics.